Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Mostrar outras versões (1)

<p><strong>Background</strong> We evaluated the use of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, for the treatment of patients admitted to hospital because of COVID-19.</p> <p><strong>Methods</strong> This randomised, controlled, open-label platform...

ver descrição completa

Detalhes bibliográficos
Principais autores: RECOVERY Collaborative Group, Horby, P, Emberson, J, Mafham, M, Campbell, M, Peto, L, Pessoa-Amorim, G, Spata, E, Staplin, N, Lowe, C, Chadwick, D, Brightling, C, Stewart, R, Collini, P, Ashish, A, Green, C, Prudon, B, Felton, T, Kerry, A, Baillie, K, Buch, M, Day, JN, Faust, S, Jaki, T, Jeffery, K, Juszczak, E, Knight, M, Lim, WS, Montgomery, A, Mumford, A, Rowan, K, Thwaites, G, Haynes, R, Landray, M
Formato: Internet publication
Idioma:English
Publicado em: 2022

Registros relacionados